In this articlePFEKena Betancur | Corbis News | Getty ImagesPfizer had a "phenomenal" first quarter — and Wall Street took notice, CEO Albert Bourla told thousands of employees during a companywide town hall on May 2, according to a recording heard by CNBC. A day earlier, the pharmaceutical giant's stock had closed 6% higher after its quarterly results topped analyst estimates and it hiked its full-year outlook. It was a far cry from the year prior, when Pfizer's shares plunged more than 40%, making it one ...

These top healthcare stocks are no-brainer buys in 2024 and beyond.This latest bull market is seeing a wave of enthusiasm from investors ... for the stocks of select companies. While some stocks are getting enthusiastic buy-in, there are plenty of others that haven't quite joined in on the market frenzy.When you're investing in stocks with a long-term mindset around a quality company's ability to execute a business plan, you can afford to be patient and eventually benefit from the growth stories it generate ...

One of the pharma giant's top-selling products is about to face some intense competition.It's no secret why Pfizer (PFE -0.82%) stock has been struggling this year. Investors are worried about how well the company will be able to do in light of waning demand for its COVID-19 vaccine and pill. It's also facing patent cliffs for many of its top drugs. That's why even though it's trading at a seemingly cheap 12 times its estimated future earnings, investors aren't piling into the stock. And now, one of its riv ...

The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for individuals 6 months of age and olderRecommendation is based on pre-clinical and epidemiological data showing that the JN.1-adapted monovalent COVID-19 vaccine generates an improved immune response against multiple JN.1 sublineagesDoses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission NEW YORK and MAINZ, Germany, June 27, 2024 — Pfizer Inc. ( ...

One company's negative results can increase scrutiny of another's work.When one player stumbles in a high-stakes competition, it's often to the glee of the other contenders. In mid-June, Pfizer's (PFE -0.86%) gene-therapy candidate to treat Duchenne muscular dystrophy (DMD) didn't hit the mark in a late-stage clinical trial; it'd be logical to assume that shares of Sarepta Therapeutics, (SRPT -1.64%) a biotech focused on developing DMD drugs, would then rise.But that didn't happen -- at least not until Sare ...

Pfizer (PFE) closed the latest trading day at $27.99, indicating a -1.3% change from the previous session's end. The stock fell short of the S&P 500, which registered a gain of 0.09% for the day. Meanwhile, the Dow lost 0.1%, and the Nasdaq, a tech-heavy index, added 0.16%.Prior to today's trading, shares of the drugmaker had lost 1.8% over the past month. This has lagged the Medical sector's gain of 2.3% and the S&P 500's gain of 2.83% in that time.The investment community will be closely monitoring the pe ...

This is a matchup that the latecomer might not be able to win.It's obvious why Pfizer (PFE -0.11%) is eager to produce a medicine like Wegovy, Novo Nordisk's (NVO 2.93%) smash-hit obesity therapy that's essentially a slightly different version of its type 2 diabetes drug called Ozempic. With such a gargantuan market at stake, there's likely more than enough room for multiple major competitors to find a home.But that doesn't mean the contenders have an equal chance of winning any competitive fight once such ...

Price only tells you part of the story.The stock market has had a roaring first half of 2024, but not all companies have seen shares respond in the same way. As always, it's important to look beyond share prices and see how the business of any stock you want to invest in is holding up.Sometimes, a beaten-down stock is a fantastic opportunity to become part owner of a business on the dip. Here are two such companies to keep in mind if you have cash on hand to invest that you don't need for bills or other nea ...

It doesn't take much to boost your passive income stream with these top dividend-paying stocks.Would you like to widen the stream of passive income you can expect each year? Managing rental property is an option, but most retirees find this method less passive than they would like it to be.Investors who are attracted to truly passive income generation may want to consider AT&T (T 1.60%), PenantPark Floating Rate Capital (PFLT -0.26%), and Pfizer (PFE). They offer an average yield of 7.6% at recent prices, s ...

Pfizer (PFE) closed at $27.41 in the latest trading session, marking a +1.59% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.25%. Elsewhere, the Dow gained 0.15%, while the tech-heavy Nasdaq added 0.03%.Prior to today's trading, shares of the drugmaker had lost 5.43% over the past month. This has lagged the Medical sector's gain of 0.11% and the S&P 500's gain of 3.34% in that time.The investment community will be closely monitoring the performance of Pfizer in its f ...